Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aerovate Therapeutics, Inc. stock logo
AVTE
Aerovate Therapeutics
$8.23
+11.5%
$8.67
$56.35
$105.00
$238.55M0.9512,438 shs124,811 shs
Cybin Inc. stock logo
CYBN
Cybin
$7.15
+3.3%
$7.68
$4.81
$13.88
$168.67M0.68320,405 shs592,928 shs
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
$19.99
+1.2%
$20.30
$2.03
$14.36
$187.87M1.1150,104 shs134,942 shs
Stellar Biotechnologies Inc stock logo
SBOT
Stellar Biotechnologies
$9.71
+5.0%
$59,624.23
$0.75
$3.25
$51.75MN/A2.95 million shs3.99 million shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aerovate Therapeutics, Inc. stock logo
AVTE
Aerovate Therapeutics
+0.27%+9.01%-17.82%+4.98%-88.78%
Cybin Inc. stock logo
CYBN
Cybin
+3.32%+1.27%-7.86%-4.28%+1,837.67%
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
+0.20%-2.23%-11.59%+14.29%-44.89%
Stellar Biotechnologies Inc stock logo
SBOT
Stellar Biotechnologies
-0.11%-9.14%-15.68%-18.43%-17.63%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aerovate Therapeutics, Inc. stock logo
AVTE
Aerovate Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Cybin Inc. stock logo
CYBN
Cybin
2.4338 of 5 stars
3.60.00.00.01.70.81.3
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Stellar Biotechnologies Inc stock logo
SBOT
Stellar Biotechnologies
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aerovate Therapeutics, Inc. stock logo
AVTE
Aerovate Therapeutics
0.00
N/AN/AN/A
Cybin Inc. stock logo
CYBN
Cybin
3.25
Buy$85.001,088.81% Upside
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
0.00
N/AN/AN/A
Stellar Biotechnologies Inc stock logo
SBOT
Stellar Biotechnologies
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest SBOT, AVTE, NLTX, and CYBN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/8/2025
Cybin Inc. stock logo
CYBN
Cybin
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$73.00 ➝ $70.00
(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aerovate Therapeutics, Inc. stock logo
AVTE
Aerovate Therapeutics
N/AN/AN/AN/A$3.96 per shareN/A
Cybin Inc. stock logo
CYBN
Cybin
N/AN/AN/AN/A$10.83 per shareN/A
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
N/AN/AN/AN/A$11.08 per shareN/A
Stellar Biotechnologies Inc stock logo
SBOT
Stellar Biotechnologies
$210K246.45N/AN/A$2.12 per share4.58
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aerovate Therapeutics, Inc. stock logo
AVTE
Aerovate Therapeutics
-$75.52M-$1.70N/AN/AN/AN/A-90.19%-77.47%11/10/2025 (Estimated)
Cybin Inc. stock logo
CYBN
Cybin
-$57.88M-$4.60N/AN/AN/AN/A-37.58%-36.59%N/A
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
-$57.56M-$3.11N/AN/AN/A-37.22%-30.91%N/A
Stellar Biotechnologies Inc stock logo
SBOT
Stellar Biotechnologies
-$5.03M-$1.76N/AN/AN/A-1,782.64%-51.12%-48.37%N/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aerovate Therapeutics, Inc. stock logo
AVTE
Aerovate Therapeutics
N/AN/AN/AN/AN/A
Cybin Inc. stock logo
CYBN
Cybin
N/AN/AN/AN/AN/A
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
N/AN/AN/AN/AN/A
Stellar Biotechnologies Inc stock logo
SBOT
Stellar Biotechnologies
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aerovate Therapeutics, Inc. stock logo
AVTE
Aerovate Therapeutics
N/A
8.78
8.78
Cybin Inc. stock logo
CYBN
Cybin
N/A
24.24
24.24
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
N/A
15.33
15.33
Stellar Biotechnologies Inc stock logo
SBOT
Stellar Biotechnologies
N/A
9.24
8.96

Institutional Ownership

CompanyInstitutional Ownership
Aerovate Therapeutics, Inc. stock logo
AVTE
Aerovate Therapeutics
N/A
Cybin Inc. stock logo
CYBN
Cybin
17.94%
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
52.37%
Stellar Biotechnologies Inc stock logo
SBOT
Stellar Biotechnologies
1.69%

Insider Ownership

CompanyInsider Ownership
Aerovate Therapeutics, Inc. stock logo
AVTE
Aerovate Therapeutics
24.90%
Cybin Inc. stock logo
CYBN
Cybin
15.00%
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
1.58%
Stellar Biotechnologies Inc stock logo
SBOT
Stellar Biotechnologies
7.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aerovate Therapeutics, Inc. stock logo
AVTE
Aerovate Therapeutics
2028.99 million21.69 millionOptionable
Cybin Inc. stock logo
CYBN
Cybin
5023.59 million17.96 millionNot Optionable
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
909.40 million9.25 millionNo Data
Stellar Biotechnologies Inc stock logo
SBOT
Stellar Biotechnologies
255.33 millionN/ANot Optionable

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aerovate Therapeutics stock logo

Aerovate Therapeutics NASDAQ:AVTE

$8.23 +0.85 (+11.52%)
As of 08/22/2025

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Cybin stock logo

Cybin NYSE:CYBN

$7.15 +0.23 (+3.32%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$7.16 +0.01 (+0.21%)
As of 08/22/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds. The company has research and collaboration agreement with TMS Neurohealth Centers Inc. for development of psychedelic compound-based therapeutics; Kernel for use of Kernel flow technology to measure neural activity; and Greenbook TMS to establish mental health centers. The company is headquartered in Toronto, Canada.

Neoleukin Therapeutics stock logo

Neoleukin Therapeutics NASDAQ:NLTX

$19.99 +0.24 (+1.22%)
As of 08/22/2025

Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.

Stellar Biotechnologies stock logo

Stellar Biotechnologies NASDAQ:SBOT

Stellar Biotechnologies, Inc., a biotechnology company, engages in the aquaculture, research and development, manufacture, and commercialization of keyhole limpet hemocyanin (KLH) protein in Europe, North America, and Asia. The company offers KLH, an immune-stimulating protein used in the production of various immunotherapies; and as a carrier molecule or finished injectable product in the immunodiagnostic market. It provides its KLH protein under the Stellar KLH brand. The company's products include Stellar KLH protein in various grades, formulations, custom configurations, and fill finishes for drug development and research applications, as well as KLH-based in vitro diagnostic kits for research and preclinical use. Its customers and partners comprise biotechnology and pharmaceutical companies, academic institutions, clinical research organizations, and research centers. Stellar Biotechnologies, Inc. is based in Port Hueneme, California.